Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05907980 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
A Phase 1 study of Solid Tumor, sponsored by Chugai Pharmaceutical.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 219
- Enrollment target
- 4
- Study locations
NCT05907980: Recruiting Phase 1 study of Solid Tumor, sponsored by Chugai Pharmaceutical.
NCT05907980 is a Phase 1 study of Solid Tumor that is actively recruiting participants, run by Chugai Pharmaceutical. The registered enrollment target is 219 participants, roughly in line with the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target. The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05907980, a Phase 1 study of Solid Tumor, is actively recruiting participants, sponsored by Chugai Pharmaceutical.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 219 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a Phase Ia/Ib open-label, dose-escalation study to evaluate the safety and pharmacokinetics of ROSE12 as a single agent and in combination with other anti-tumor agents in patients with locally advanced or metastatic solid tumors. The study will consist of three parts: a dose-escalation part, a biopsy part (the part to evaluate biomarkers), and an expansion part.
Primary Outcome
Incidence and nature of dose-limiting toxicities (DLTs)
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG ROSE12
Study Locations (4)
Texas
- MD Anderson Cancer Center - Houston
Virginia
- NEXT Oncology - Fairfax
Chiba
- National Cancer Center Hospital East - Kashiwa-shi
Tokyo
- National Cancer Center Hospital - Chuo-ku
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 219 participants |
| Start Date | 2023-05-24 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
What NCT05907980 shows while recruiting
NCT05907980 is an interventional study that assigns participants to a tested intervention. The registered 219 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target.
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Atezolizumab is the first listed.
NCT05907980 reports a single indexed study location in Texas, Virginia, Chiba.
Frequently Asked Questions
What is clinical trial NCT05907980 about?
NCT05907980 is a clinical study titled "A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors". This is a Phase Ia/Ib open-label, dose-escalation study to evaluate the safety and pharmacokinetics of ROSE12 as a single agent and in combination with other anti-tumor agents in patients with locally advanced or metastatic solid tumors. The study will consist of three parts: a dose-escalation part,...
What is the current status of trial NCT05907980?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 219 participants. The study started on 2023-05-24. Estimated completion is 2026-12-31.
What conditions does trial NCT05907980 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT05907980?
The interventions under investigation include: Atezolizumab (DRUG), ROSE12 (DRUG).
Who is sponsoring clinical trial NCT05907980?
This trial is sponsored by Chugai Pharmaceutical, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05907980 being conducted?
This trial has 4 study locations across Texas, Virginia, Chiba, Tokyo. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05907980's enrollment target sits among peer trials
219 35th of 196 higher than 162 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05196035 · 219 participants · Phase 3
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
- NCT05608434 · 219 participants · Phase 1
Development of Virtual Reality-based Interventions to Strengthen Cognitive Skillsets Related to Attention Deficit Hyperactivity Disorder (ADHD): A Pilot Phase I and Randomized Controlled Phase II Trial
- NCT05773144 · 219 participants · NA
Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon Cancer
- NCT06014255 · 219 participants · Phase 2
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI